Balaji Prasad
Stock Analyst at Barclays
(3.35)
# 1,016
Out of 5,006 analysts
132
Total ratings
48.39%
Success rate
3.05%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.48 | +286.10% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $10.44 | +5.36% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.89 | +0.48% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $10.18 | -11.55% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $137.49 | +45.47% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $20.75 | -8.43% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $67.17 | -10.67% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $145.77 | +67.39% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $10.90 | +120.28% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $38.30 | -42.56% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $629.61 | -17.41% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $19.94 | +30.42% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.15 | +20.14% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.53 | +111.02% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.52 | +184.09% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.69 | +314.20% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.48
Upside: +286.10%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $10.44
Upside: +5.36%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.89
Upside: +0.48%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $10.18
Upside: -11.55%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $137.49
Upside: +45.47%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $20.75
Upside: -8.43%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $67.17
Upside: -10.67%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $145.77
Upside: +67.39%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $10.90
Upside: +120.28%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $38.30
Upside: -42.56%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $629.61
Upside: -17.41%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $19.94
Upside: +30.42%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.15
Upside: +20.14%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.53
Upside: +111.02%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.52
Upside: +184.09%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.69
Upside: +314.20%